Users' Opinions

Trusted across pharma, academia and biotech
I'm Interested

Explore our Users’ Opinions

Prof. Daniel Otzen

Aarhus Univeristy
Professor, Interdisciplinary Nanoscience Centre (iNano)

''And I believe that FIDA could really become a basically standard technique within the pharmaceutical industry.''

Prof. Alexander Kai Büll

Danish Technical University
Professor DTU BIOENGINEERING Institut for Biotechnology & Biomedicine

''With relatively short training, implementing the methods that we're developing, a user can actually quantify the thermodynamics of phase separation.''

Prof. dr. Stefan Rüdiger

Utrecht Univeristy
Professor for Protein Chemistry of Disease

''FIDA is actually the only technique now that allows us to measure the size of protein fibrils, and also the monitoring of the length and increase or shrinkage of fibrils''

Prof. Dr. Markus Gräler

Jena University Hospital
Head of the Sepsis Research Group

''And now we are able to really focus on even large patient cohorts with a couple of hundred patients that we are able to process with the FIDA technology. And that makes it very versatile for us.''

Jan S. Nowak, Ph.D.

Aarhus Univeristy
Core Facility Manager & Staff Scientist, Department of Molecular Biology & Genetics

''So we had to find a solution for measuring them in solution and FIDA has been really excellent for this.''

Opinion on FIDA for studying intermolecular protein associations
Prof. Daniel Otzen
Aarhus Univeristy
Opinion on FIDA for Liquid-Liquid Phase Separation
Prof. Alexander Kai Büll
Danish Technical University
Opinion on FIDA for research on amyloid fibrils
Prof. dr. Stefan Rüdiger
Utrecht Univeristy
Opinion on Using FIDA for Translational Research
Prof. Dr. Markus Gräler
Jena University Hospital
Opinion on FIDA for Protein Biophysics at a Core Facility
Jan S. Nowak, Ph.D.
Aarhus Univeristy
Loxo Lilly
Modena
Agilent
Novartis
GSK
Beam
Lilly
Sanofi
Astra Zeneca
Novo Nordisk
Bristol Myers Sqibb
Merck
UT Southwestern
EPFL
Phy6bio
VIB VUB
University of Copenhagen
University Jena
Universiteit Utrecht
Uni Greiburg
IGBMC
Ensoma
LMU
Spolight
Peak
NW
Institut
Eurofins
DTU
Diamond
Aarchus
Francis
Monte Rosa
MIP Discovery

This methodology is very sensitive and useful for assessing binding in a quantitative manner using small amounts of auto-fluorescent proteins. Using this method, we can observe clear changes in apparent hydrodynamic radius (Rh) and in fluorescence signal of EYA1 as a function of increasing concentrations of peptides or of small molecules

Dana Farber Institute
CANCER INSTITUTE
Dana Farber Institute
CANCER INSTITUTE

Cellular Protein Chemistry, Bijvoet Centre and Science for Life Utrecht University

''Fida  Instrument provides a ''ruler'' to measure the length of fibrils''

Stefan Rüdiger Ph.D.
Professor of Protein Chemistry of Disease; Head of Department of Chemistry
Stefan Rüdiger Ph.D.
Professor of Protein Chemistry of Disease; Head of Department of Chemistry

Astbury Centre for Structural Molecular Biology, University of Leeds

''The FIDA is very effective for screening small molecules for solubility and interactions with protein targets. A major advantage has been its ability to clearly show drug binding to difficult-to-work-with targets such as intrinsically disordered proteins and amyloids''

Dr. Alexander Taylor
Research Fellow in Biochemistry/Biophysics
Dr. Alexander Taylor
Research Fellow in Biochemistry/Biophysics

Karolinska Institutet

I would say that this instrument is quite useful for core facilities at KI or for Swedish research community in general:

  1. it was possible to measure unlabeled membrane proteins and soluble proteins at low concentrations in small volumes very fast (~6 minutes per measurement).
  2. I also like the temperature control and the autosampler which allowed us to run a lot of samples overnight.
  3. I would say that there is a lot of potential to perform other assays as well, such as the Kd determinations etc. (For this, I use ITC which is quite time-consuming and requires a lot of protein).
  4. In addition, the software and user interface for sample runs and data analysis is quite straightforward and intuitive to use.
Postdoctoral Researcher
Postdoctoral Researcher

Peak Proteins - Sygnature Discovery

"What we value about FIDA is the amount of information we can get from a tiny amount of protein in a single QC run. FIDA technology enables us to understand our proteins better - particularly when they behave in unexpected ways. We chose FIDA because it gives us that vital first result quickly - we don't waste our time optimising an assay that isn't going to work."

Duncan Smith
Lead Scientist
Duncan Smith
Lead Scientist

Novartis Institutes for BioMedical Research (NIBR)

"I am convinced. I have never before been able to detect the ternary construct formation of my construct directly in cell lysate – it took less than two hours."

Thomas Smith
Associate Director, Chemical Biology & Therapeutics
Thomas Smith
Associate Director, Chemical Biology & Therapeutics

Bristol-Myers Squibb

"The Fida 1’s unique capability for measuring binding Kd from weak mM level to strong pM level really enhances our bioanalytical capabilities."

Sherry Zhu
Senior Scientist
Sherry Zhu
Senior Scientist

Technical University of Denmark

"FIDA is an in-solution technique, and thus an ideal binding assay for structurally diverse bsAbs because the analysis does not rely on potentially obstructive surface immobilization and hence it is able to perform characterizations that are unbiased by bsAb format and spatial orientation of the binding domains."

Andreas V. Madsen
PhD Student
Andreas V. Madsen
PhD Student

Francis Crick Institute

"After thorough comparisons, it was clear that the Fida 1, amongst others, presents unique opportunities in analysis of membrane proteins, which is essential to us."

Svend Kjæer
STP Deputy
Svend Kjæer
STP Deputy

National Physcal Labolatory, UK

''The Fida 1 system offers a new approach to detergent screening that has significant advantages allowing essential data to be obtained faster using less material (…) this work presents a new approach to characterize membrane proteins that allows users to reducing costs and time as well as to analyze protein expressed at low levels in a short time thus overcoming any stability issues.''

Isabel Moraes
Principal Research Scientist
Isabel Moraes
Principal Research Scientist
Amy Danson
Higher Research Scientist

IGBMC

"I like the ease of use and the straightforward data analysis and, that experiments can be performed in any type of buffers. We get data, where no other biophysical methods worked before."

Cathrine Birck
Head of Integrated Structural Biology Platform
Cathrine Birck
Head of Integrated Structural Biology Platform

Arbor Biotechnologies

"The method is easy to setup in any standard laboratory and can be adopted for a high throughput (HTTP) screening, which enabled mechanistic studies of RNA nuclease interactions, as well as efficient guide RNA lead discovery (…) Fida 1 offers straightforward assay development, walk away automation, absolute measurement and ultra low sample consumption."

Denny Truong
Principal Research Associate
Denny Truong
Principal Research Associate

Institute for Chemistry and Bioanalytics

"FIDA provides in-depth assessment of activity combined with local and global protein structural changes by measuring the overall hydrodynamic radius of the protein with minimal sample consumption. In addition, it is possible to measure the affinity constant for the analyzed interaction."

Dr. Melanie Hug
Research Associate
Dr. Melanie Hug
Research Associate

Peak Proteins - Sygnature Discovery

"The beauty of Fida 1 is that it allows us to conduct a lot of biophysical measurements in one system using a small amount of reagent and a rapid read-out time which is important for our projects and to our customers. (…) Providing a high-quality, protein characterisation QC package is certainly extending and future proofing our capabilities in biophysical characterisation of the proteins we produce."

Mark Abbott
Managing Director
Mark Abbott
Managing Director

MIP Discovery

"The Fida 1 has allowed us to assess the performance of MIPs with a much higher throughput than was previously possible on other platforms. MIPs can be developed in as little as 8 weeks, which is a significant improvement on antibodies, and now they can be fully characterized at an accelerated pace too."

Alan Thomson
CEO
Alan Thomson
CEO

C4 Therapeutics

"Fida 1 can be used for full characterization of ternary complex formation for targeted protein degradation. The Fida 1 platform only consumes 39 nL of sample for one measurement and thus allows elaborate condition screening using very small amounts of sample material."

Roman Agafonov
Associate Director of Biochemistry, Biophysics & Structural Biology
Roman Agafonov
Associate Director of Biochemistry, Biophysics & Structural Biology
Scott Eron
Senior Research Scientist

Try it yourself.

Your laboratory instruments should serve you, not the other way around.